Cargando…

The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab

SIMPLE SUMMARY: Non-resectable biliary tract cancer is incurable. The balance between last-line treatment, with limited improvement in survival, and potential adverse events calls for prognostic biomarkers aiding the decision making process. The aim of this retrospective study was to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersen, Line Bechsgaard, Mahler, Marit Sofie Kjær, Andersen, Rikke Fredslund, Jensen, Lars Henrik, Raunkilde, Louise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558975/ https://www.ncbi.nlm.nih.gov/pubmed/36230519 http://dx.doi.org/10.3390/cancers14194598

Ejemplares similares

NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
por: Raunkilde, Louise, et al.
Publicado: (2022)

Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA
por: Kjær, Ina Mathilde, et al.
Publicado: (2023)

The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer
por: Wen, Sara Witting Christensen, et al.
Publicado: (2021)

NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Wen, Sara Witting Christensen, et al.
Publicado: (2023)

Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer
por: Faaborg, Louise, et al.
Publicado: (2022)

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
por: Hansen, Torben Frøstrup, et al.
Publicado: (2017)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer
por: Thomsen, Caroline Emilie B., et al.
Publicado: (2017)

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
por: Goff, Laura W., et al.
Publicado: (2016)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib
por: Tomar, Shubham, et al.
Publicado: (2022)

Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication
por: Hoshino, Yoshinori, et al.
Publicado: (2014)

Protection of Upper Respiratory Tract, Mouth and Eyes
por: Andersen, Bjørg Marit
Publicado: (2018)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
por: Forthun, Rakel Brendsdal, et al.
Publicado: (2019)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
por: Yasui, Hirotoshi, et al.
Publicado: (2014)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group
por: Callesen, Louise Bach, et al.
Publicado: (2023)

Quantification of microRNA levels in plasma – Impact of preanalytical and analytical conditions
por: Binderup, Helle Glud, et al.
Publicado: (2018)

Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients
por: Borg, Morten, et al.
Publicado: (2022)

Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
por: Spindler, Karen Lise Garm, et al.
Publicado: (2015)

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
por: Yau, Thomas, et al.
Publicado: (2012)

Quantification of microRNA in plasma using probe based TaqMan assays: is microRNA purification required?
por: Binderup, Helle Glud, et al.
Publicado: (2019)

Elevated Levels of PGE2-Metabolite in Cerebrospinal Fluid and Cox-2 Gene Polymorphisms in Patients with Chronic, Post Cholecystectomy Pain and Visceral Hyperalgesia Compared to Healthy Controls. A Hypothesis-Generating Pilot Study
por: Blichfeldt-Eckhardt, Morten Rune, et al.
Publicado: (2022)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

The Homeobox Only Protein Homeobox (HOPX) and Colorectal Cancer
por: Yamashita, Keishi, et al.
Publicado: (2013)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
por: Deng, Wusheng, et al.
Publicado: (2022)

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
por: Bozec, A, et al.
Publicado: (2008)

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study
por: Fukuhara, Tatsuro, et al.
Publicado: (2020)

A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma
por: El-Khouly, Fatma E., et al.
Publicado: (2021)

Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy
por: Eriksen, Anne Haahr Mellergaard, et al.
Publicado: (2017)

BILIARY TRACT DISORDERS
Publicado: (1984)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uek3k6snle6tpd0tn4rp8l5ukh